FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an ester presented by formula [2] where R1' represents 1) C1-C6 alkyl which is optionally substituted by one or more identical or different halogens, or 2) -CO-C1-C6 alkoxy; R2' represents 1) hydrogen or 2) C1-C6 alkyl, R3', R4' and R5' are identical or different, and each represents 1) hydrogen, 2) halogen, 3) C1-C6 alkyl which is optionally substituted by one or more identical or different halogens, 4) C1-C6 alkoxy, 5) -COR13' where R13' represents (a) hydroxy, (b) C1-C6 alkyl, (c) C1-C6 alkoxy which is optionally substituted by one or more identical or different substitutes selected from (1) hydroxy, (2) C1-C6 alkoxy which is optionally substituted by phenyl, (3) -NR11'CO-C1-C6 alkyl where R11' represents hydrogen, (4) -CONR8'R9' where R8' and R9' are identical or different, and each represents C1-C6 alkyl, (5) -CO- C1-C6 alkoxy optionally substituted by phenyl, (6) phenyl optionally substituted by one or more identical or different substitutes selected from halogen, C1-C6 alkoxy and -CO-C1-C6 alkoxy, and (7) a heterocycle selected from pyridyl, thienyl and 
which all can be substituted by one or more identical or different C1-C6 alkyl groups, or (d) -OR19' where R19' represents a group 
or a group 
or piperidyl which is optionally substituted by -CO-C1-C6alkyl, 6) a heterocycle selected from oxadiazolyl and tetrazolyl, and said heterocycle is optionally substituted by C1-C6 alkyl optionally substituted by one or more identical or different substitutes selected from -CONR8'R9' (R8' and R9' have the same values as defined above) and -CO-aralkyloxy, or 7) nitrile; R6' and R7' are identical or different, and each represents 1) C1-C6 alkyl or 2) a nitrogen-containing 5 or 6-members saturated heterocycle containing a monocycle formed when R6', R7' and a neighbouring nitrogen atom are taken together, and optionally including oxygen as a heteroatom; Y1, Y2, Y3 are identical or different, and represent, 1) all carbon atoms, or 2) one of Y1, Y2, Y3 represent a nitrogen atom, and the others are carbon atoms; Y4 represent a carbon or nitrogen atom ;-X- represents 1) -(CH2)1 where 1 represents an integer 1 to 3, 2) -CH2-NR18'-CH2- where R18' represents C1-C6 alkyl, or 3) 
or to its pharmaceutically acceptable salt.
EFFECT: compounds presented by formula 
are effective as agents for treatment or prevention hyperlipidemia, arteriosclerosis, coronary artery disease, obesity, diabetes and hypertension or similar diseases since they are withdrawn very quickly and exhibit excellent MTP inhibitory activity.
23 cl, 32 tbl, 137 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ESTER COMPOUNDS AND THEIR USING IN MEDICINE | 2003 |
|
RU2293721C2 |
| RETINOID-LIKE COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 1996 |
|
RU2163590C2 |
| SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINEAMIDES AND THEIR DERIVATIVES, METHODS OF TREATMENT OF PATIENTS AND PHARMACEUTICAL COMPOSITION | 1996 |
|
RU2143424C1 |
| SUBSTITUTED PYRAZOLES, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF CATHEPSIN S ACTIVITY | 2001 |
|
RU2278863C2 |
| ANTIBACTERIAL AGENTS | 1999 |
|
RU2246941C2 |
| 2-THIO SUBSTITUTED DERIVATIVES OF IMIDAZOLE AND THEIR USE IN PHARMACEUTICALS | 2003 |
|
RU2331638C2 |
| PYRROLE DERIVATIVES AS MEDICINAL SUBSTANCES | 2005 |
|
RU2470916C2 |
| PROLYL HYDROXYLASE INHIBITORS AND APPLICATION METHODS THEREOF | 2007 |
|
RU2429226C9 |
| USING IkB KINASE INHIBITOR IN ANESTHETIZING TREATMENT | 2003 |
|
RU2320338C2 |
| COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA-2-ADRENERGIC RECEPTOR AGONIST ACTIVITY | 2013 |
|
RU2661877C2 |
